Fierce Biotech March 15, 2024
Oxford Nanopore Technologies has signed a partnership with artificial intelligence developer SeqOne to support its next-generation sequencing approach in clinical diagnostic testing.
The goal will be to provide an end-to-end platform that applies extra-long nanopore sequencing reads to whole genomes—initially in order to help identify variants associated with rare diseases, before expanding the project’s scope into cancer testing.
The two companies are starting by connecting SeqOne’s germVar application with Oxford Nanopore’s EPI2ME bioinformatics analysis software, currently limited to research use only.
“Combining nanopore sequencing data with SeqOne’s AI-powered variant interpretation platform will support the time-sensitive workflows of our clinical customers, and we look forward to advancing their research and supporting future clinical use,” Oxford Nanopore CEO Gordon Sanghera, Ph.D., said...
Today's Sponsors
Today's Sponsor